Background and Aims: Bronchodilators are the cornerstone of
Hallym University Sacred Heart Hospital, South Korea Methods: This is a randomized, multicentre, open-label, parallel group, 12-week, trial in mild-to-moderate COPD patients who received TIO 18 μg q.d. for at least 12 weeks prior to study initiation. COPD patients, aged ≥ 40 years, with post-bronchodilator forced expiratory volume in 1 second (FEV 1 ) ≥ 50% of predicted normal value and post-bronchodilator FEV 1 /force vital capacity (FVC) < 0.7, and a smoking history of at least 10 pack-years were included. The primary objective of this study is to demonstrate the superiority of IND/GLY 110/50 μg q.d. over TIO 18 μg q.d. in terms of pre-dose trough FEV 1 following 12 weeks of treatment. Secondary endpoints include the pre-dose trough FEV 1 after 4 weeks of treatment, transition dyspnea index (TDI) total score, COPD assessment test (CAT) total score, and rescue medication use following the 12-week treatment, and safety assessment over the 12-week treatment.
Results: In total, 442 patients were screened; of these, 378 patients were randomized to IND/GLY 110/50 μg q.d. and TIO 18 μg q.d. A total of 347 patients completed the study. The study is expected to demonstrate the superiority of IND/GLY 110/50 μg q.d. over TIO 18 μg q.d. in COPD patients with mild-to-moderate airflow limitation.
Conclusion:
Results from this study will add to the existing evidence supporting the greater efficacy of IND/GLY over TIO in patients with COPD. Obstructive Pulmonary Disease (COPD) by degrading a wide range of extracellular matrix proteins and thereby causing emphysema. Inhibition of neutrophil elastase by small molecule would prevent the severe tissue damage which might be useful to manage COPD. The aim of the present study is to screen small molecules for their anti-elastase activity and characterize them in vitro.
Methods: Synthetic molecules were screened on the basis of enzyme-substrate kinetic reactions for 2 h in the absence or presence of a known inhibitor. Potential inhibitors were sorted and IC 50 values were determined. in vitro assays were carried out to evaluate binding kinetics, potency, enzyme selectivity and bioavailability. in vitro morphological studies were conducted and cell toxicity was determined by MTT assay while cardiac toxicity by automated patch clamp method (hERG).
Results: Out of 50 small molecules, initial screening showed a benzoxazin derivative as good potential inhibitor with an IC 50 value of 150 nM as compared to control drug. The lead compound was found to be a reversible and competitive neutrophil elastase inhibitor. The compound was bioavailable and selective towards neutrophil elastase as compared to other endogenous enzymes. The compound prevented cellular desquamation and also showed protective effect against elastase induced cellular morphological changes and toxicity.
Based on the present study a benzoxazin group containing novel synthetic compound is found to be a selective inhibitor of human neutrophil elastase with good efficacy in in-vitro models and has the potential to be effective against neutrophil driven inflammatory lung diseases such as COPD. Background and Aims: The aim of was to evaluate the predictive value and prognostic value of peripheral blood eosinophils for acute exacerbation risk in patients with chronic obstructive pulmonary disease (COPD).
Methods: This study was designed as an observational project in hospitalized COPD patients with acute exacerbation. They were divided into the eosinophil group (peripheral blood eosinophil continue no less than 2%) and the non-eosinophil group (eosinophil continue less than 2%). Their hospital stay, dosage of intravenous use of corticosteroids, neutral lymphocyte to lymphocyte ratio (NLR), eosinophil to basophil ratio (EBR), number of exacerbations that occurred during one year's follow-up were compared.
Results: The eosinophil group involved 25 cases, the other group involved 33 cases. Age, gender, BMI, smoking history, hs-CRP, peripheral white blood cell count, FEV1% predicted had no statistical difference. The eosinophil group had shorter hospitalization days in acute exacerbations (7.68 AE 1.70 vs 9.00 AE 2.67, P < 0.05) and less dosage of intravenous use of corticosteroids (105.6 AE 123.90 mg vs 225.76 AE 76.77 mg, P < 0.05) compared with non-eosinophil group. The eosinophil group had significantly lower NLR and percentage of peripheral blood neutrophils (both P < 0.05). The percentage of peripheral blood lymphocytes and EBR were higher in the eosinophil group than those in the non-eosinophil group (both P < 0.05). We observed higher numbers of exacerbations occurred during one year's follow-up in the non-eosinophil group (2.13 AE 1.46) compared to the eosinophil group (1.11 AE 1.05). Only one patient died within one year's follow-up after discharge in the eosinophil group, and the other group had eight deaths
